Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This multicentre pilot trial will assess the feasibility of a full-scale, randomized trial to determine whether bloodwork guided dosing of blood thinners reduces the risk of clotting in high-risk trauma patients. Patients will receive either standard of care dosing or dosing with adjustments based on bloodwork to achieve a minimum therapeutic threshold.
This multicentre pilot trial will assess the feasibility of a full-scale, randomized trial to determine whether anti-Xa guided dosing of low molecular heparin (LMWH) reduces the risk of venous thromboembolism (VTE) in high-risk trauma patients. Patients will receive either standard of care fixed dosing of Enoxaparin or 0.5 mg/kg twice daily with dose adjustments to achieve an anti-Xa trough level between 0.1 and 0.2 IU/mL.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Standard of Care | Active Comparator | Participants will receive Enoxaparin dosed at the discretion of the most responsible physician (MRP). In cases of severe renal insufficiency (CrCl < 30mL/min^:), the LMWH may dose reduced or changed to Heparin at the discretion of the MRP. |
|
| Intervention (Anti-Xa Guided) | Experimental | Participants will receive Enoxaparin 0.5 mg/kg twice daily (rounded up or down to the nearest 10 mg) the initial starting dose. Dose adjustments will be made based on trough levels drawn between the 3rd and 4th dose. The target anti-Xa level range is between 0.1 and 0.2 IU/mL. If the patient is below the target range, then the next Enoxaparin dose will be increased by 10 mg per dose with a new trough anti-Xa level 24 hours after dose modification. If the patient is above the target range, then the next Enoxaparin dose will be decreased by 10 mg per dose with a new trough anti-Xa level 24 hours after dose modification. This dose will be maintained until hospital discharge. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Anti-Xa Guided Dosing of Low Molecular Weight Heparin | Drug | Participants will receive Enoxaparin 0.5 mg/kg twice daily (rounded up or down to the nearest 10 mg) the initial starting dose. Dose adjustments will be made based on trough levels drawn between the 3rd and 4th dose. The target anti-Xa level range is between 0.1 and 0.2 IU/mL. If the patient is below the target range, then the next Enoxaparin dose will be increased by 10 mg per dose with a new trough anti-Xa level 24 hours after dose modification. If the patient is above the target range, then the next Enoxaparin dose will be decreased by 10 mg per dose with a new trough anti-Xa level 24 hours after dose modification. This dose will be maintained until hospital discharge. |
| Measure | Description | Time Frame |
|---|---|---|
| Recruitment (Patients per site per month) | The pilot trial will have an expected duration of 15 months during which time we hope to enroll at least 150 participants total across all sites - therefore, 5 patients/site/month. There are no maximum enrollment targets for each site. | Participants per site per month x 15 months |
| Measure | Description | Time Frame |
|---|---|---|
| Eligibility rate | Proportion of screened patients who are eligible | 15 months |
| Consent rate | Proportion of eligible patients who provide consent |
Not provided
Inclusion Criteria:
To be eligible, patients must be deemed appropriate for pharmacologic prophylaxis by the most responsible physician and randomized with the intention to receive prophylaxis within 48 hours of admission. Prior to randomization, there is no restriction on whether or not patients have previously received pharmacologic or mechanical prophylaxis.
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Alexandre Tran, MD, MSc, FRCSC | Contact | 613-737-8899 | 17076 | aletran@toh.ca |
| Rebecca Porteous, RN, BNSC, CCRP | Contact | 613-737-8899 | 17076 | rporteous@ohri.ca |
| Name | Affiliation | Role |
|---|---|---|
| Alexandre Tran, MD, MSc, FRCSC | Ottawa Hospital Research Institute | Principal Investigator |
| Marc Carrier, MD, MSc, FRCPC | Ottawa Hospital Research Institute | Principal Investigator |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Standard of Care Dosing | Drug | Participants will receive Enoxaparin dosed at the discretion of the most responsible physician (MRP). In cases of severe renal insufficiency (CrCl < 30mL/min^:), the LMWH may dose reduced or changed to Heparin at the discretion of the MRP. |
|
| 15 months |
| Retention rate | Proportion of participants retained at follow-up | 15 months |
| Study completion rate | Proportion of participants who completed all study procedures | 15 months |
| Adherence rate | Adherence to study drug measured by proportion of prophylaxis doses received. | 15 months |
| Adherence to monitoring | Proportion of patients with anti-Xa tests ordered appropriately | 15 months |
| Adherence to dose adjustment | Proportion of doses adjusted appropriately for anti-Xa level | 15 months |
| Adherence to anti-Xa target | Proportion of patients who achieved target anti-Xa range | 15 months |
| Reasons for declining participation | Reasons for declining participation | 15 months |
| ID | Term |
|---|---|
| D054556 | Venous Thromboembolism |
| D014947 | Wounds and Injuries |
| ID | Term |
|---|---|
| D013923 | Thromboembolism |
| D016769 | Embolism and Thrombosis |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided